Company intelligence
BigHat Biosciences
BigHat Biosciences is a novel protein therapeutics company and developer of an AI-guided antibody design platform
About BigHat Biosciences
BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.
Verified activity
Signals from BigHat Biosciences
8 published signals
People
BigHat Biosciences welcomed Vivian Ngo to the Platform team as a Research Associate I.
Reported by BigHat Biosciences
People
BigHat Biosciences welcomed Omar Nayfeh to the Platform team as a Research Associate II.
Reported by BigHat Biosciences
People
BigHat Biosciences welcomed Emma Scaff to the Platform team as a Research Associate I.
Reported by BigHat Biosciences
Research & Knowledge
BigHat Biosciences announced that the first patient has been treated in its Phase 1 trial of BHB810, a CDH17-directed antibody-drug conjugate for advanced gastric cancer.
Reported by BigHat Biosciences
Research & Knowledge
BigHat Biosciences reported that someone with advanced gastric cancer received the first dose of BHB810 in a Phase 1 trial.
Reported by Keltoum Boukra
Research & Knowledge
BigHat Biosciences is treating patients with investigational medicines from its lab with extraordinary clinical potential.
Reported by Ryan Henrici MD PhD
Research & Knowledge
BigHat Biosciences is thanking participants in its clinical trial for their sacrifices required to make every clinic visit, attend every blood draw and scan, and provide extra support.
Reported by Ryan Henrici MD PhD
Products & Services
BigHat Biosciences announced that its first patient was dosed with its AI for science platform.
Reported by Phillip M. Maffettone